Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
ESMO Open ; 6(1): 100010, 2021 02.
Artículo en Inglés | MEDLINE | ID: mdl-33399076

RESUMEN

BACKGROUND: The implementation of multidisciplinary tumor board (MDTB) meetings significantly ameliorated the management of oncological diseases. However, few evidences are currently present on their impact on pancreatic cancer (PC) management. The aim of this study was to evaluate the impact of the MDTB on PC diagnosis, resectability and tumor response to oncological treatment compared with indications before discussion. PATIENTS AND METHODS: All patients with a suspected or proven diagnosis of PC presented at the MDTB from 2017 to 2019 were included in the study. Changes of diagnosis, resectability and tumor response to oncological/radiation treatment between pre- and post-MDTB discussion were analyzed. RESULTS: A total of 438 cases were included in the study: 249 (56.8%) were presented as new diagnoses, 148 (33.8%) for resectability assessment and 41 (9.4%) for tumor response evaluation to oncological treatment. MDTB discussion led to a change in diagnosis in 54/249 cases (21.7%), with a consequent treatment strategy variation in 36 cases (14.5%). Change in resectability was documented in 44/148 cases (29.7%), with the highest discrepancy for borderline lesions. The treatment strategy was thus modified in 27 patients (18.2%). The MDTB brought a modification in the tumor response assessment in 6/41 cases (14.6%), with a consequent protocol modification in four (9.8%) cases. CONCLUSIONS: MDTB discussion significantly impacts on PC management, especially in high-volume centers, with consistent variations in terms of diagnosis, resectability and tumor response assessment compared with indications before discussion.


Asunto(s)
Enfermedades Pancreáticas , Neoplasias Pancreáticas , Humanos , Estudios Interdisciplinarios , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/terapia , Centros de Atención Terciaria
2.
Eur Rev Med Pharmacol Sci ; 23(19): 8625-8629, 2019 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-31646596

RESUMEN

OBJECTIVE: Cannabis is an illegal drug that has been under the spotlight in recent years, due to its vast array of effects on different biological systems. The role of cannabis has been investigated in the management of pain in acute pancreatitis (AP), even though some studies suggest that it may have a causative effect in this pathology and could be considered the underlying etiology in some cases of idiopathic AP. In this case report, we discuss the case of a young man who presented with three different episodes of AP, with apparently no significant history of alcohol and drug consumption, and with no evidence of a biliary, genetic or, autoimmune etiology. During the third episode, in which he had developed a voluminous pseudocyst, treated trough ultrasound (EUS)-guided drainage, he admitted consumption of cannabis daily. The Naranjo score resulted to be 6 (confirming the possible causality), and it was suggested to the patient to avoid cannabis consumption. Since then, he did not develop any other AP episodes. In summary, cannabis should be considered among the possible AP etiologies, as its causative identification and interruption may significantly improve the course of several idiopathic APs.


Asunto(s)
Cannabinoides/efectos adversos , Cannabis/efectos adversos , Pancreatitis/inducido químicamente , Adulto , Humanos , Masculino , Pancreatitis/diagnóstico por imagen
3.
Eur Rev Med Pharmacol Sci ; 23(2): 771-787, 2019 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-30720186

RESUMEN

Acute pancreatitis (AP) is the most common gastrointestinal disorder requiring hospitalization, with a high rate of morbidity and mortality. Severe AP is characterized by the presence of persistent organ failure involving single or multiple organs. Clinical evolution, laboratory and radiological assessment are necessary to evaluate the prognosis and inform the management of AP. The onset of severe AP may be classified in two principal phases. The early phase, during the first week, is characterized by the activation of the auto-inflammatory cascade, gut dysbiosis, bacterial translocation, and the down-regulation of immune responses. The late phase is characterized by the development of local and systemic complications. Several old paradigms have been amended in the management of AP patients, such as the indication of nutrition, the use of antibiotic therapy, pain control strategies, and even the use of surgery. Real world evidence has shown that in the majority of cases a step-up approach is most effective. In this review, we discuss the clinical assessment and improvements to the management of patients with severe AP in a high volume center where a multi-disciplinary approach is performed.


Asunto(s)
Insuficiencia Multiorgánica/terapia , Dolor/tratamiento farmacológico , Pancreatitis/terapia , Grupo de Atención al Paciente , Analgésicos/uso terapéutico , Antibacterianos/uso terapéutico , Traslocación Bacteriana/inmunología , Colangiopancreatografia Retrógrada Endoscópica , Drenaje/métodos , Gastroenterostomía , Microbioma Gastrointestinal/inmunología , Humanos , Insuficiencia Multiorgánica/inmunología , Terapia Nutricional/métodos , Dolor/inmunología , Manejo del Dolor/métodos , Páncreas/diagnóstico por imagen , Páncreas/inmunología , Páncreas/patología , Páncreas/cirugía , Pancreatitis/complicaciones , Pancreatitis/diagnóstico , Pancreatitis/inmunología , Índice de Severidad de la Enfermedad , Tomografía Computarizada por Rayos X
4.
Eur Rev Med Pharmacol Sci ; 21(22): 5179-5184, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-29228431

RESUMEN

Pancreatic cystosis is a rare presentation of cystic fibrosis involving pancreatic gland. To date, only very few cases of pancreatic cystosis have been described in literature. Pancreatic cystosis may begin during the second decade of life and is the rarest presentation of cystic fibrosis. This disease is characterized by the presence of multiloculated cysts without ductal system communication of different sizes in all the pancreatic tissue. Herein, we report a case of a young woman affected by cystic fibrosis that was admitted to our Pancreatic Centre to evaluate a picture of diffuse multiloculated pancreatic cysts. After magnetic resonance imaging (MRI) and endoscopic ultrasound (EUS) assessment, we perform the diagnosis of the concomitant presence of the rare condition of pancreatic cystosis with Branch Duct-Intraductal Papillary Mucinous Neoplasm (BD-IPMN). To our knowledge, this is the first reported case of a cystic fibrosis patient with the combination of pancreatic cystosis and IPMN.


Asunto(s)
Adenocarcinoma Mucinoso/complicaciones , Fibrosis Quística/complicaciones , Quiste Pancreático/complicaciones , Papiloma Intraductal/complicaciones , Adenocarcinoma Mucinoso/diagnóstico por imagen , Fibrosis Quística/diagnóstico por imagen , Endosonografía , Femenino , Humanos , Imagen por Resonancia Magnética , Persona de Mediana Edad , Páncreas/diagnóstico por imagen , Quiste Pancreático/diagnóstico por imagen , Papiloma Intraductal/diagnóstico por imagen
5.
Eur Rev Med Pharmacol Sci ; 21(12): 2858-2874, 2017 06.
Artículo en Inglés | MEDLINE | ID: mdl-28682431

RESUMEN

Intraductal Papillary Mucinous Neoplasms (IPMNs) are the most common cystic tumors of the pancreas and are considered premalignant lesions. IPMNs are characterized by the papillary growth of the ductal epithelium with rich mucin production, which is responsible for cystic segmental or diffuse dilatation of the main pancreatic duct (MPD) and/or its branches. According to the different involvement of pancreatic duct system, IPMNs are divided into main duct type (MD-IPMN), branch duct type (BD-IPMN), and mixed type (MT-IPMN). IPMNs may be incidentally discovered in asymptomatic patients, particularly in those with BD-IPMNs, when imaging studies are performed for unrelated indications. The increase in their frequency may reflect the combined effects of new diagnostic techniques, the improvement of radiologic exams and progress in the recognition of the pathology. MD-IPMNs present a higher risk of malignant progression than BD-IPMNs; as a consequence, all the guidelines strictly suggest the need of surgery for MD- and MT- IPMNs with MPD > 10 mm, while the management of BD-IPMNs is still controversial and depends on several cysts and patients features. The choice between non-operative and surgical management depends on the distinction between benign and invasive IPMN forms, assessment of malignancy risk, patient's wellness and its preferences. This manuscript revises the different guidelines for the management of IPMNs that have been published in different world countries: the international (Sendai 2006 and Fukuoka 2012), the 2013 European, the 2014 Italian, and finally the 2015 American guidelines. In summary, this review will integrate the recent insights in the combination of diagnostic techniques, such as Magnetic Resonance Imaging (MRI) and endoscopic ultrasound (EUS), pathology classification, and management of IPMNs.


Asunto(s)
Adenocarcinoma Mucinoso/terapia , Adenocarcinoma Papilar/terapia , Conductos Pancreáticos/diagnóstico por imagen , Conductos Pancreáticos/patología , Neoplasias Pancreáticas/terapia , Guías de Práctica Clínica como Asunto , Adenocarcinoma Mucinoso/diagnóstico por imagen , Adenocarcinoma Mucinoso/patología , Adenocarcinoma Papilar/diagnóstico por imagen , Adenocarcinoma Papilar/patología , Endosonografía , Humanos , Imagen por Resonancia Magnética , Neoplasias Pancreáticas/diagnóstico por imagen , Neoplasias Pancreáticas/patología
7.
G Ital Med Lav Ergon ; 32(2): 154-61, 2010.
Artículo en Italiano | MEDLINE | ID: mdl-20684436

RESUMEN

There is no universally approved method in the scientific literature to identify subjects exposed to asbestos and divide them in classes according to intensity of exposure. The aim of our work is to study and develope an algorithm based on the findings of occupational anamnestical information provided by a large group of workers. The algorithm allows to discriminate, in a probabilistic way, the risk of exposure by the attribution of a code for each worker (ELSA Code--work estimated exposure to asbestos). The ELSA code has been obtained through a synthesis of information that the international scientific literature identifies as the most predictive for the onset of asbestos-related abnormalities. Four dimensions are analyzed and described: 1) present and/or past occupation; 2) type of materials and equipment used in performing working activity; 3) environment where these activities are carried out; 4) period of time when activities are performed. Although it is possible to have informations in a subjective manner, the decisional procedure is objective and is based on the systematic evaluation of asbestos exposure. From the combination of the four identified dimensions it is possible to have 108 ELSA codes divided in three typological profiles of estimated risk of exposure. The application of the algorithm offers some advantages compared to other methods used for identifying individuals exposed to asbestos: 1) it can be computed both in case of present and past exposure to asbestos; 2) the classification of workers exposed to asbestos using ELSA code is more detailed than the one we have obtained with Job Exposure Matrix (JEM) because the ELSA Code takes in account other indicators of risk besides those considered in the JEM. This algorithm was developed for a project sponsored by the Italian Armed Forces and is also adaptable to other work conditions for in which it could be necessary to assess risk for asbestos exposure.


Asunto(s)
Amianto/efectos adversos , Asbestosis/epidemiología , Mesotelioma/epidemiología , Exposición Profesional/efectos adversos , Neoplasias Pleurales/epidemiología , Algoritmos , Asbestosis/complicaciones , Asbestosis/prevención & control , Humanos , Italia/epidemiología , Mesotelioma/etiología , Mesotelioma/prevención & control , Metaanálisis como Asunto , Neoplasias Pleurales/etiología , Neoplasias Pleurales/prevención & control , Valor Predictivo de las Pruebas , Medición de Riesgo , Encuestas y Cuestionarios
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA